Clinical trials
Chronic kidney disease clinical trials
A gradual loss of kidney function over time. We’re tracking 571 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06990672Enrolling by invitation
WeChat therapy to help kidney stone patients drink more water
This study tests if a WeChat-based digital program can help people who've had kidney stone surgery increase their daily fluid intake to prevent new stones. You might qualify if you drink less than 2.5 liters of fluid per day and use WeChat regularly.
Shenzhen, GuangdongAges 18 years+ - NCT05213598Recruiting
Biomarker study for liver disease after Fontan surgery
This study looks for blood and/or test markers that can better show how severe liver disease is in people who had the Fontan heart procedure. It also involves medical imaging and/or a liver biopsy or related procedures to help evaluate those markers.
Bethesda, MarylandAges 18–100 - NCT00001971Recruiting
Evaluation of patients with liver disease
This research study evaluates people with liver disease or at risk for liver disease, and compares them with healthy volunteers. The goal is to better understand liver disease and improve how doctors diagnose and treat it.
Bethesda, MarylandAges 2–100 - NCT05705414RecruitingEarly Phase 1
Amino acid supplement during dialysis to improve energy in kidney disease
This early-stage study tests whether taking amino acids during hemodialysis can help people with end-stage kidney disease feel better and maintain strength. It may help by supporting nutrition during dialysis, but it’s mainly meant to gather early safety and benefit information.
San Antonio, TexasAges 18–64 - NCT05917795Recruiting
Endoscopic stomach reduction for weight loss before kidney transplant
This trial tests an endoscopic procedure that helps reduce stomach size to support weight loss in people with severe kidney disease who may need a kidney transplant. It may help some patients meet transplant-center weight requirements and potentially improve readiness for transplant care.
RomeAges 18–70 - NCT05715814RecruitingPhase 3
Test diabetes-pill type medicine on kidney dialysis safety
This Phase 3 trial studies the safety of an SGLT2 inhibitor (a diabetes medication that can affect kidney fluid handling) in people on peritoneal dialysis. The goal is to see how the treatment works in your type of dialysis and whether it causes any problems.
Toronto, OntarioAges 18 years+ - NCT03884075RecruitingPhase 2
Semaglutide study for fatty liver and how sugar affects the liver
This Phase 2 study tests how semaglutide (a diabetes medication also used for weight) affects fatty liver and the liver’s response to sugar. It may help people with non-alcoholic fatty liver disease understand whether the drug improves liver fat and related changes.
Bethesda, MarylandAges 18–100 - NCT06903559RecruitingPhase 1/Phase 2
Roxadustat for heart and nutrition in dialysis patients
This study tests whether roxadustat can help improve heart health, nutrition, and reduce inflammation in people on hemodialysis. It may offer a new treatment option for anemia related to kidney disease.
Al Mansurah, DakahliyaAges 18 years+ - NCT05642156Recruiting
Ultrafiltration versus usual dialysis in people on hemodialysis
This study compares a specific way of removing fluid during dialysis (isolated ultrafiltration) with conventional hemodialysis. It aims to see how each approach affects blood flow and fluid shifts in people with end-stage kidney disease.
GrazAges 18 years+ - NCT00977977RecruitingPhase 2
Rituximab plus cyclosporine for membranous kidney disease
This trial tests whether rituximab (an immune-targeting medicine) plus cyclosporine (another immune medicine) can better control protein leakage in the urine for people with idiopathic membranous nephropathy. It may help reduce long-lasting kidney damage risk when standard treatments like ACE inhibitor or ARB don’t control the protein level.
Bethesda, MarylandAges 18–90 - NCT06092333RecruitingPhase 2
New combo therapy for chronic hepatitis B
This trial tests a new medicine (VIR-2218) combined with a standard injection (peginterferon) to see if it can better control chronic hepatitis B. It may be an option if your virus levels are low and you haven't had recent treatment.
Bethesda, MarylandAges 18–65 - NCT06285279RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune kidney diseases
This trial tests a new type of cell therapy called CAR-T cells that target two proteins (BCMA and CD19) to treat autoimmune kidney diseases that are not responding to standard treatments. The goal is to see if this therapy can help control the disease and improve kidney function.
Nanjing, JiangsuAges 18–65 - NCT07403669Recruiting
Heart, kidney, and metabolic health assessment study
This trial offers a health assessment and empowerment program for adults who have heart, kidney, or metabolic conditions like diabetes or heart disease. It aims to help you better manage your health.
Chandler, ArizonaAges 18 years+ - NCT03049462RecruitingPhase 1
Study how a beta-3 drug changes body fat in healthy adults
This Phase 1 study tests how chronic treatment with a beta-3–type medicine affects brown fat (a special kind of body fat) in the body. It mainly looks at safety and how the body responds over time, which could help future treatments for weight and metabolic health.
Bethesda, MarylandAges 18–40 - NCT07191561Recruiting
Liver fat and alcohol use disorder study
This trial looks at how the liver processes fat in people with alcohol use disorder. It may help find better ways to treat liver problems related to drinking.
Bethesda, MarylandAges 18–100 - NCT06749457RecruitingPhase 1/Phase 2
Study of a new drug for healthy adults and kidney patients on dialysis
This trial tests a new drug called AZD7760 in two groups: healthy adults (Phase I) and adults with end-stage kidney disease who are on hemodialysis through a central venous catheter (Phase IIa). The goal is to see how safe the drug is and how the body processes it. This could lead to a new treatment option for people on dialysis.
Huntsville, AlabamaAges 18–55 - NCT07571746RecruitingPhase 2
Surovatamig for antibody-mediated kidney disease
This study tests a new medicine called surovatamig for adults with a specific type of kidney disease caused by the body's own antibodies (anti-PLA2R antibody-positive membranous nephropathy). The medicine may help reduce kidney damage and improve kidney function.
Los Angeles, CaliforniaAges 18–75 - NCT07745920Recruiting
An online program for depression in people with adpkd
This study tests an internet-based program to help manage depression symptoms in people with ADPKD. The program may be a convenient way to get support for your mood without traveling to a clinic.
Rochester, MinnesotaAges 18–70 - NCT05828823Recruiting
Two-times-a-week dialysis for new patients
This study tests whether starting dialysis at twice a week, instead of the usual three times, is safe and effective for people who still have some kidney function. If the kidneys still make urine and clear waste, being on dialysis less often may maintain that function longer.
Jacksonville, FloridaAges 18 years+ - NCT06958016Recruiting
Tryptase levels in stable coronary artery disease
This study looks at levels of tryptase, a protein in your blood, in people with stable coronary artery disease. It aims to see if these levels are linked to heart health, which could help doctors better understand and manage your condition.
Athens, AtticaAges 18–85 - NCT06714006RecruitingPhase 1
Testing safety of PYC-003 for ADPKD
This study is testing a new investigational medicine called PYC-003 for people with autosomal dominant polycystic kidney disease (ADPKD). It is one of the first studies in humans, so the main goal is to see if the medicine is safe and tolerable. The study is for people with a specific genetic cause (PKD1 mutation) and with certain kidney imaging types.
Southport, Gold CoastAges 18–65 - NCT04685200Recruiting
Study causes of primary sclerosing cholangitis using body scans
This study looks at what drives primary sclerosing cholangitis (PSC) and how it affects the body, using a team approach and medical tests like scans and blood work. It may help researchers understand PSC better and could improve future treatment decisions.
Bethesda, MarylandAges 18–90 - NCT04799301RecruitingPhase 1
Measure how much sugar you eat using blood and hair samples
This Phase 1 study tests whether “biomarkers” in your blood and hair can accurately measure how much sugar you consume. It may help researchers find better ways to track dietary sugar intake in future nutrition and health studies.
Phoenix, ArizonaAges 18–65 - NCT05159466Recruiting
Transplant from HIV-positive donors to HIV-positive recipients
This trial studies whether it’s safe and effective for HIV-positive people to receive organ transplants from HIV-positive donors. It focuses on matching HIV treatment before and after transplant and checking for major complications.
Metairie, LouisianaAges 18 years+
Hear when a new Chronic kidney disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic kidney disease?
- Yes. Clin2 currently lists 571 recruiting chronic kidney disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic kidney disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic kidney disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.